Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Otto-von-Guericke University Magdeburg
Magdeburgo, AlemaniaPublicaciones en colaboración con investigadores/as de Otto-von-Guericke University Magdeburg (21)
2024
2023
-
Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)
Frontiers in Pharmacology
-
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study
JHEP Reports, Vol. 5, Núm. 2
-
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
JHEP Reports, Vol. 5, Núm. 5
-
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
European Radiology, Vol. 33, Núm. 1, pp. 493-500
-
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients
Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309
-
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Frontiers in Pharmacology, Vol. 14
2022
-
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726
-
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485
-
Dynamics in Circulating Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial
Frontiers in Gastroenterology, Vol. 1
-
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
Cancer Imaging, Vol. 22, Núm. 1
-
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria
Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901
-
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 9, pp. 2487-2496
-
Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT
Clinical Colorectal Cancer, Vol. 21, Núm. 4, pp. 285-296
2021
-
Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)
CardioVascular and Interventional Radiology, Vol. 44, Núm. 1, pp. 21-35
-
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 75, Núm. 6, pp. 1387-1396
-
Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
EJNMMI Research, Vol. 11, Núm. 1
2020
-
Reply to: “Toxicity and dosimetry in SORAMIC study”
Journal of Hepatology
2019
-
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 71, Núm. 6, pp. 1164-1174
2017
-
Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review
Hepatology, Vol. 66, Núm. 3, pp. 969-982